NCT05256108View on ClinicalTrials.gov

Assessment of Abuse Potential of Cebranopadol in Humans

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

July 12, 2022

Study Completion Date

July 12, 2022

Conditions
Human Abuse Potential
Interventions
DRUG

Oxycodone 40 mg

Participants will be administered a single dose of 6 capsules containing oxycodone and placebo in a randomized crossover manner

DRUG

Tramadol 600 mg

Participants will be administered a single dose of 6 capsules containing tramadol in a randomized crossover manner

DRUG

Placebo

Participants will be administered a single dose of 6 capsules containing placebo in a randomized crossover manner

DRUG

Cebranopadol 600 µg

Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner

DRUG

Cebranopadol 1000 µg

Participants will be administered a single dose of 6 capsules containing cebranopadol and placebo in a randomized crossover manner

Trial Locations (1)

43212

Ohio Clinical Trials, Columbus

All Listed Sponsors
lead

Tris Pharma, Inc.

INDUSTRY